Keyword Analysis & Research: tnkase genentech

Keyword Analysis


Keyword CPC PCC Volume Score Length of keyword
tnkase genentech0.60.918386016
tnkase0.760.86900676
genentech0.480.36637439

Keyword Research: People who searched tnkase genentech also searched

Keyword CPC PCC Volume Score
tnkase genentech1.970.7539628
genentech tnkase returns1.460.1589475
genentech tnkase replacement1.540.29043100

Search Results related to tnkase genentech on Search Engine

  • Genentech: TNKase® (tenecteplase) - Information for …

    gene.com

    https://www.gene.com/patients/medicines/tnkase

    TNKase is the first thrombolytic that can be administered over five seconds in a single dose, offering physicians the fastest administration of a thrombolytic to date in the treatment of heart attack. TNKase is a bioengineered variant of Activase® (Alteplase, recombinant), which is a recombinant DNA-derived version of … See more

    DA: 14 PA: 34 MOZ Rank: 7

  • Genentech Pro | TNKase® (tenecteplase)

    genentech-pro.com

    https://www.genentech-pro.com/product-information/products/tnkase.html

    WEBProducts. TNKase ® (tenecteplase) TNKase Website. Prescribing Information. Dosing & Administration. Safety. Access Solutions Quick Enroll. My Patient Solutions Login. …

    DA: 58 PA: 64 MOZ Rank: 7

  • TNKase® Dosing, Administration, and Reconstitution

    tnkase.com

    https://www.tnkase.com/dosing-and-administration/dosing-administration-and-reconstitution.html

    WEBStep 1. Determine the correct dose of TNKase based on patient weight. TNKase is for IV administration only. Step 2. WITHDRAW the appropriate volume of solution based on …

    DA: 22 PA: 41 MOZ Rank: 46

  • Tenecteplase Thrombolysis for Acute Ischemic Stroke

    ahajournals.org

    https://www.ahajournals.org/doi/10.1161/STROKEAHA.120.029749

    WEBOct 13, 2020 · Tenecteplase achieved regulatory approval in the US (TNKase; Genentech) and Europe (Metalyse; Boehringer Ingelheim) in the year 2000 as a tiered weight-based … Author: Steven J. Warach, Adrienne N. Dula, Truman J. Milling Publish Year: 2020

    Author: Steven J. Warach, Adrienne N. Dula, Truman J. Milling

    Publish Year: 2020

    DA: 63 PA: 33 MOZ Rank: 22

  • TNKase® Dosing, Administration, and Reconstitution

    tnkase.com

    https://www.tnkase.com/dosing-and-administration/dosing-administration-and-reconstitution.html

    DA: 21 PA: 7 MOZ Rank: 5

  • Confirming the Benefits of Tenecteplase for Acute …

    neurologylive.com

    https://www.neurologylive.com/view/confirming-benefits-tenecteplase-acute-ischemic-stroke-timeless

    WEBDec 23, 2021 · THE PHASE 3 TRIAL CALLED Thrombolysis in Imaging-eligible, Late-window Patients to Assess the Efficacy and Safety of …

    DA: 34 PA: 43 MOZ Rank: 60

  • Is Tenecteplase Ready for Prime Time in Acute Stroke?

    tctmd.com

    https://www.tctmd.com/news/tenecteplase-ready-prime-time-acute-stroke

    WEBMar 19, 2021 · Whether the evidence supports wider use of tenecteplase (TNKase; Genentech)—a thrombolytic agent with an indication for acute MI—as an alternative to alteplase (Activase; Genentech) for the …

    DA: 46 PA: 53 MOZ Rank: 34

  • DailyMed - TNKASE- tenecteplase kit

    nih.gov

    https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=739a3c53-caf6-40d6-a6af-84ce733a948b

    WEBApr 12, 2023 · TNKase® is indicated to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI). 2 DOSAGE AND ADMINISTRATION. 2.1 …

    DA: 62 PA: 23 MOZ Rank: 68

  • FDA approves TNKase from Genentech

    thepharmaletter.com

    https://www.thepharmaletter.com/article/fda-approves-tnkase-from-genentech

    WEBApr 6, 2000 · Genentech's new-generation thrombolytic TNKase (tenecteplase) has beenapproved by the US Food and Drug Administration for the treatment of acute …

    DA: 94 PA: 47 MOZ Rank: 12